

Research v1.0 release notes

Editorial update: September 28, 2026 | Maher Chaar, PharmD | Unified ACB Tool

Scope and status

Research v1.0 is a bounded release of an evidence directory and experimental model methods. It is not a validated medication-list risk calculator. This expanded editorial edition explains what the original research freeze included and how the public articles relate to it. The original two-page release note is preserved in the research archive.

Frozen research assets

The underlying database is the byte-for-byte v0.14.0_ROUTE_FORMULATION_RC snapshot incorporated into research v1.0. Its recorded SHA-256 is 9ed990bcaacf5c9e1213f9097550787890e014233d75597eb02b931a593aa607. The original package comprised one workbook and eight PDF documents. The five printable website articles were created later and do not replace that historical freeze.

Inventory and audit

The directory has 557 distinct medication records and 1,977 scale-observation rows; observations are not unique published references. All 200 deeper-audited priority records have a named scale rating. In that group, 127 CALS matches were supported by the original publication or footnotes, 196 imported KABS rows still required independent primary-row checks, and 39 had different KABS and CALS categories. Among 357 other records, 333 had literal-name evidence matches at shallower depth and 24 needed identity or evidence review. Five catalog entries repaired 476 missing definition references, three empty definition IDs were linked, and five historical Final pharmacokinetic citation gaps were backfilled. This improved traceability, not primary-row verification. These groups describe audit status, not clinical harm.

Model and outcome status

Twenty archived 0-10 estimates are qualified by regimen and assay, including 18 rat-brain binding inputs and two human M1 cases. They are not validated whole-drug or patient scores. Chlorpromazine and clomipramine were moved from an earlier Final status to provisional after active-moiety review. An earlier NHANES cognition analysis used a historical 22-drug freeze and found a qualified association; its complete-routed-list restriction did not clearly associate. An independent MEPS 2024 primary cognitive-limitation analysis was null (adjusted OR per SD 1.009; 95% CI 0.927-1.098; n=6,112). The current 20-estimate audit was not prospectively tested in either survey.

Website publications and provenance

Five public reports describe the evidence inventory, experimental 0-10 model, cognitive outcome analyses, future delirium protocol, and website display design. Each has a permanent URL and printable PDF with a figure, table, definitions, and external references. The dated original source documents remain in the archive. A printable article is a website edition, not a new independent study. A PDF may contain interpretation and editorial explanation beyond the frozen source summary; this does not change the underlying data.

Open work and limits

Primary supplement row checks, medication identity and formulation review, active-metabolite coverage, assay comparability, reuse review, and independent dose-aware outcome validation remain open. A proposed medication-administration-record delirium study has not been executed. The public site asks visitors not to enter patient identifiers. AI contributed extensively to evidence organization, analysis, writing, and development; independent review is needed. Visitors should verify primary sources and use clinical judgment. A missing model value is unknown, never a zero or safety finding.

Selected source publications

1. Rudolph JL, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508-513. doi:10.1001/archinternmed.2007.106
2. Jun K, et al. Development of an anticholinergic burden scale specific for Korean older adults. Geriatr Gerontol Int. 2019;19:628-634. doi:10.1111/ggi.13680
3. Ramos H, et al. CRIDECO Anticholinergic Load Scale. J Pers Med. 2022;12:207. doi:10.3390/jpm12020207
4. Vennard O, et al. Anticholinergic medication burden scales: a systematic review. J Am Geriatr Soc. 2026;74:1771-1784. doi:10.1111/jgs.70352
5. AGS Beers Criteria Update Expert Panel. 2023 AGS Beers Criteria. J Am Geriatr Soc. 2023;71:2052-2081. doi:10.1111/jgs.18372

For numeric project findings, see the original archived release note and validation report at unifiedacb.com/research, along with methods and references in the five printable research articles.